December 10, 2021 07:23 AM ESTUpdated 08:11 AM

Snakebit Angion reports another miss for lead program, as biotech prepares to shift its 'primary focus'

Max Gelman

Senior Editor

Angion’s lead organ damage drug took two strikes earlier this year, flopping as a repurposed effort for Covid-19 and whiffing in high-risk kidney transplant patients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Snakebit Angion reports another miss for lead program, as biotech prepares to shift its 'primary focus'

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Gilead buys experimental HIV vaccines from a small Barcelona biotech

Snakebit An­gion re­ports an­oth­er miss for lead pro­gram, as biotech pre­pares to shift its 'pri­ma­ry fo­cus'

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Bio­haven's myo­statin in­hibitor miss­es pri­ma­ry end­point in spinal mus­cu­lar at­ro­phy tri­al

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

Snakebit Angion reports another miss for lead program, as biotech prepares to shift its 'primary focus'

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Gilead buys experimental HIV vaccines from a small Barcelona biotech